Probiotic + metformin trial in T2DM adults, Hohhot, China
96 gut metagenome samples from adult type 2 diabetes patients in Hohhot, China, from a randomized, double-blind, placebo-controlled trial testing probiotic (Probio-X) coadministration with metformin versus metformin alone. machine-written summary
96 samples · 96 runs · CN · Adult · 2023 · 6.87 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 768 sample values (collection date, country, intervention, latitude, location locality, longitude, subject id, timepoint) |
| ○ Abstract / description | read; no usable statement |
| ✓ Full text | 384 sample values (antibiotic exposure, health condition, health condition detail, location site) · PMC9948714 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention · arms resolved
Probiotic (live microorganisms; single strain or mixture) design randomized_controlled_trial · population type2_diabetes · Probio-X probiotic plus metformin vs placebo plus metformin, 3 months
“randomized, double-blind, placebo-controlled clinical trial” — abstract:36688679 (study level; per-sample arms are in the intervention column below)
longitudinal — not resolved
48 of 48 people sampled more than once (96 samples; median 2, up to 2 per person).
Genera, mean relative abundance over 87 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 96 | 100% | ||||
| country | 96 | 100% | 96 | |||
| health_condition | 96 | 100% | 96 | |||
| subject_id | 96 | 100% | 96 | |||
| antibiotic_exposure | 96 | 100% | 96 | |||
| collection_date | 96 | 100% | 96 | |||
| detailed_location | 96 | 100% | ||||
| health_condition_detail | 96 | 100% | 96 | |||
| intervention | 96 | 100% | 96 | |||
| latitude | 96 | 100% | 96 | |||
| location_locality | 96 | 100% | 96 | |||
| location_site | 96 | 100% | 96 | |||
| longitude | 96 | 100% | 96 | |||
| timepoint_label | 96 | 100% | 96 |
- Adjunctive Probio-X Treatment Enhances the Therapeutic Effect of a Conventional Drug in Managing Type 2 Diabetes Mellitus by Promoting Short-Chain Fatty Acid-Producing Bacteria and Bile Acid Pathways. 2023 PMID 36688679 PMC9948714 own_data
Archive description
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease. As a commonly used drug for the treatment of T2DM, metformin will gradually reduce the efficacy or cause gastrointestinal dysfunction with the prolongation of treatment time. The gut microbiota may be the target of metformin, and probiotics can target and modulate the gut microbiota. Our study suggests that probiotics and metformin can further modulate the metabolism of host bile acids or SCFAs by mediating the gut microbiota in patients with T2DM, thereby enhancing the hypoglycemic effect of metformin.
How this project entered the registry
Classified as human blood / tissue / internal fluids / gut / stool shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site study.title · “acid-producing bacteria and bile acid pathways”
- body site study.description · “metabolism of host bile acids or SCFAs”
- body site study.description · “efficacy or cause gastrointestinal dysfunction with the”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN26350919 | antibiotic_exposure | no | R3 | 0.70 | paper.fulltext.methods | had taken no antibiotics within 1 month before the trial |
| SAMN26350919 | collection_date | 2019-03-12/2019-06-12 | R1 | 0.90 | biosample.attribute:collection_date | 2019-03-12/2019-06-12 |
| SAMN26350919 | country | CN | R1 | 0.90 | sample.attr.geo_loc_name | China:Hohhot |
| SAMN26350919 | health_condition | type2_diabetes | R3 | 0.70 | paper.fulltext.methods | 58 patients who were clinically diagnosed with T2DM |
| SAMN26350919 | health_condition_detail | type 2 diabetes mellitus (T2DM) | R3 | 0.70 | paper.fulltext.methods | 58 patients who were clinically diagnosed with T2DM |
| SAMN26350919 | intervention | probiotic | R1 | 0.85 | biosample.attribute:description | Probiotics |
| SAMN26350919 | latitude | 40.5100 | R1 | 0.90 | biosample.attribute:lat_lon | 40.51 N 110.46 E |
| SAMN26350919 | location_locality | Hohhot | R1 | 0.85 | biosample.attribute:geo_loc_name | China:Hohhot |
| SAMN26350919 | location_site | Inner Mongolia People's Hospital | R3 | 0.70 | paper.fulltext.methods | Inner Mongolia People's Hospital (Hohhot, China) |
| SAMN26350919 | longitude | 110.4600 | R1 | 0.90 | biosample.attribute:lat_lon | 40.51 N 110.46 E |
| SAMN26350919 | subject_id | 10 | R1 | 0.70 | sample.name_rule:alias | Sample_10A |
| SAMN26350919 | timepoint_label | A | R1 | 0.70 | sample.name_rule:alias | Sample_10A |
Sequencing
96 runs over 96 samples · mean 7.03 Gbp per run (median 6.87 Gbp, total 674.83 Gbp; 96 runs with a base count) · layout PAIRED 96 · platform ILLUMINA 96 · models Illumina HiSeq 2500 (96) · 91% of runs with a Sandpiper profile · first public 2023-01-16
Downloads
PRJNA811727.csv.gz (3.5 KB) · parquet (74.8 KB) — all 96 samples, every field with route and confidence · PRJNA811727_determinations.csv.gz (8.0 KB) — 1,152 evidence rows